Professor Sir Andrew Pollard FMedSci
BSc MBBS PhD (Lond), DIC, MRCP (UK), FHEA, FIDSA, FRCPCH, MA, FMedSci
Professor of Paediatric Infection and Immunity
Current research activities include clinical trials of new and improved vaccines for children and adults, surveillance of invasive bacterial diseases and pneumococcal vaccine impact in children in Nepal, studies of cellular and humoral immune responses to glycoconjugate and typhoid vaccines, and development of a serogroup B meningococcal vaccine.
Professor Pollard is Director of the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford and an honorary consultant paediatrician at Oxford Children’s Hospital and Fellow of St Cross College. He received a knighthood in the Queen’s Birthday Honours in 2021 for services to Public Health, especially in the pandemic.
His research includes the design, development and clinical evaluation of vaccines in UK, Asia, Africa and Latin America, including those for typhoid, meningococcus, Haemophilus influenzae type b, pneumococcus, plague, pertussis, influenza, rabies, coronavirus and Ebola, and leads studies using a human challenge model of paratyphoid and typhoid. He was the chief investigator for the clinical trials of the Oxford-AstraZeneca vaccine in 2020, which led to authorisation of the vaccine for use in more than 170 countries with over 1 billion doses distributed by mid-July 2021. He has supervised 37 PhD students and his publications includes over 500 manuscripts and books on various topics in paediatrics and infectious diseases. He chairs the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation, is a member of WHO’s Strategic Advisory Group of Experts. He received the Bill Marshall Award of the European Society for Paediatric Infectious Disease (ESPID) in 2013, the ESPID Distinguished Award for Education and Communication in 2015 and the Rosén von Rosenstein medal in 2019 awarded by the Swedish Paediatric Society and the Swedish Society of Medicine. He was elected to the Academy of Medical Sciences in 2016.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Willingness of children and adolescents to have a COVID-19 vaccination: results of a large whole schools survey in England
FAZEL M. et al, (2021), E Clinical Medicine
Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus.
Lin G-L. et al, (2021), Nat Commun, 12
A Bayesian approach for estimating typhoid fever incidence from large-scale facility-based passive surveillance data.
Phillips MT. et al, (2021), Stat Med
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Madhi SA. et al, (2021), Lancet HIV